Thrombospondin and osteopontin bind to insulin-like growth factor (IGF)-binding protein-5 leading to an alteration in IGF-I-stimulated cell growth.

Insulin-like growth factor (IGF)-binding protein-5 (IGFBP-5) has been shown to bind to extracellular matrix (ECM) with relatively high affinity, but the ECM components that mediate this interaction have not been identified. These studies show that radiolabeled IGFBP-5 specifically coprecipitates with two ECM proteins, thrombospondin-1 (TSP-1) and osteopontin (OPN). As TSP-1 binds avidly to heparin, as does IGFBP-5, the effect of glycosaminoglycans on the TSP-1/IGFBP-5 interaction was analyzed. Heparan and dermatan sulfate inhibited binding, whereas heparin increased binding. Chondroitin sulfate A and B had no effect. In contrast, both heparin and heparan sulfate significantly inhibited the OPN-IGFBP-5 interaction and chondroitin sulfate A, B, and C had no effect. To determine the region of IGFBP-5 that was involved in each interaction, synthetic peptides that spanned several regions of IGFBP-5 were tested for their capacity to competitively inhibit coprecipitation. A peptide that contained the amino acids between positions 201 and 218 resulted in 76% and 86% inhibition of binding to TSP-1 and OPN, respectively. Three other synthetic peptides that spanned regions ofIGFBP-5 with several charged residues had no effect. IGFBP-5 mutants that contained substitutions for basic residues in the 201-218 region were tested for their ability to bind to TSP-1 or OPN. A mutant with substitutions for amino acids at positions R201 and K202 and a mutant with substitutions for K211, R214, K217, and R218 had the greatest reduction in binding to TSP-1. Mutants containing substitutions for R214 alone and the combined K217A, R218A mutant had the greatest reductions in OPN binding. When the smooth muscle cell growth response to these components was assessed, IGF-I plus IGFBP-5 or the combination of TSP-1 or OPN with IGF-I potentiated the IGF-I effect. The addition of IGFBP-5 to these combinations resulted in further significant growth stimulation. Both OPN and TSP-1 specifically bind to IGFBP-5 with high affinity. These interactions may be important for concentrating intact IGFBP-5 in extracellular matrix and for modulating the cooperative interaction between the IGF-I receptor and integrin receptor signaling pathways.

[1]  D. Clemmons,et al.  Binding of insulin-like growth factor (IGF)-binding protein-5 to smooth-muscle cell extracellular matrix is a major determinant of the cellular response to IGF-I. , 1998, Molecular biology of the cell.

[2]  W. Frazier,et al.  Identification of a new cell adhesion motif in two homologous peptides from the COOH-terminal cell binding domain of human thrombospondin. , 1993, The Journal of biological chemistry.

[3]  M. Baccarani-Contri,et al.  Osteopontin is a constitutive component of normal elastic fibers in human skin and aorta. , 1995, Matrix biology : journal of the International Society for Matrix Biology.

[4]  M. Binoux,et al.  Analysis of serum insulin-like growth factor binding proteins using western blotting: use of the method for titration of the binding proteins and competitive binding studies. , 1986, Analytical biochemistry.

[5]  D. Clemmons,et al.  A factor contained in plasma is required for IGF binding protein‐1 to potentiate the effect of IGF‐I on smooth muscle cell DNA synthesis , 1990, Journal of cellular physiology.

[6]  D. Clemmons,et al.  The Effect of Extracellular Matrix Proteins on Porcine Smooth Muscle Cell Insulin-like Growth Factor (IGF) Binding Protein-5 Synthesis and Responsiveness to IGF-I* , 1998, The Journal of Biological Chemistry.

[7]  M. Runge,et al.  β3 Integrins Are Upregulated After Vascular Injury and Modulate Thrombospondin- and Thrombin-Induced Proliferation of Cultured Smooth Muscle Cells , 1998 .

[8]  A. Chambers,et al.  Site‐directed mutagenesis of the arginine‐glycine‐aspartic acid sequence in osteopontin destroys cell adhesion and migration functions , 1995, Journal of cellular biochemistry.

[9]  R. Ross,et al.  The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. , 1995, The Journal of clinical investigation.

[10]  M. Aoyagi,et al.  Changes in osteopontin mRNA expression during phenotypic transition of rabbit arterial smooth muscle cells , 1997, Histochemistry and Cell Biology.

[11]  D. Clemmons,et al.  Identification of the Extracellular Matrix Binding Sites for Insulin-like Growth Factor-binding Protein 5* , 1996, The Journal of Biological Chemistry.

[12]  R. Hynes,et al.  Cell attachment to thrombospondin: the role of ARG-GLY-ASP, calcium, and integrin receptors , 1988, The Journal of cell biology.

[13]  R. Ross.  The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers. , 1971 .

[14]  S. Schwartz,et al.  Assessment of Factors Important in Atherosclerotic Occlusion and Restenosis , 1995, Thrombosis and Haemostasis.

[15]  C. Alpers,et al.  Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. , 1993, The Journal of clinical investigation.

[16]  D. Clemmons,et al.  Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I , 1993, The Journal of cell biology.

[17]  P. Bornstein,et al.  Diversity of Function Is Inherent in Matricellular Proteins: an Appraisal of Thrombospondin I , 1995 .

[18]  T. Nam,et al.  Insulin-like growth factor binding protein-5 binds to plasminogen activator inhibitor-I. , 1997, Endocrinology.

[19]  D. Clemmons,et al.  Insulin‐like growth factor (IGF) binding to human fibroblast and glioblastoma cells: The modulating effect of cell released IGF binding proteins (IGFBPs) , 1990, Journal of cellular physiology.

[20]  V. Swami,et al.  Thrombospondin-1 is elevated with both intimal hyperplasia and hypercholesterolemia. , 1998, The Journal of surgical research.

[21]  H. Tsuzuki,et al.  Achromobacter protease I-catalyzed conversion of porcine insulin into human insulin. , 1980, Biochemical and biophysical research communications.

[22]  T. Yue,et al.  Osteopontin-stimulated vascular smooth muscle cell migration is mediated by beta 3 integrin. , 1994, Experimental cell research.

[23]  T. Nam,et al.  Human fibroblasts secrete a serine protease that cleaves insulin-like growth factor-binding protein-5. , 1994, Endocrinology.

[24]  R. Silverstein,et al.  Tissue plasminogen activator and urokinase enhance the binding of plasminogen to thrombospondin. , 1986, The Journal of biological chemistry.

[25]  D. Clemmons,et al.  Heparin, heparan sulfate, and dermatan sulfate regulate formation of the insulin-like growth factor-I and insulin-like growth factor-binding protein complexes. , 1994, The Journal of biological chemistry.

[26]  D. Clemmons,et al.  Identification of the forms of insulin-like growth factor-binding proteins produced by human fibroblasts and the mechanisms that regulate their secretion. , 1992, The Journal of biological chemistry.

[27]  M. Somerman,et al.  Evidence that a non‐RGD domain in rat osteopontin is involved in cell attachment , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  D. Clemmons,et al.  Blocking ligand occupancy of the αVβ3 integrin inhibits insulin-like growth factor I signaling in vascular smooth muscle cells , 1998 .

[29]  E. Brown,et al.  Thrombospondin modulates alpha v beta 3 function through integrin- associated protein , 1996, The Journal of cell biology.

[30]  H. Krutzsch,et al.  Regulation of Transforming Growth Factor-β Activation by Discrete Sequences of Thrombospondin 1 (*) , 1995, The Journal of Biological Chemistry.